Study: Patient monitoring limits adverse drug effects
NEW ORLEANS – Close monitoring of patients receiving infusions of infliximab prevented adverse drug events, according to a new study from Option Care. The study included 291 Option Care patients who received 1,866 infusions of infliximab, an immune system suppressant used to treat a variety of autoimmune disorders, including rheumatoid arthritis and Crohn’s disease. Among the study’s findings: None of the infusions were associated with a severe ADE; 13 were associated with a moderate ADE, such as fever; and 65 were associated with a mild ADE, such as headache. “Our findings add to the growing body of evidence that home infusion administered by a high quality provider is safe and effective,” said Kendra Curry, PharmD, corporate director of Option Care Specialty Infusion Programs, in a release.